{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:26Z","timestamp":1791308846261,"version":"4.3.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010135","name":"The Medical Society of Finland)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Finnish Society for Study of Infectious Diseases"},{"name":"Finnish Foundation for Research on Viral Diseases"},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004155","name":"Magnus Ehrnrooth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008397","name":"Finnish Society of Sciences and Letters","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VTR\u2013State Funding for"},{"name":"Medical Research in University Hospitals"},{"name":"EU Horizon VEO and DURABLE"},{"name":"Sakari Alhopuro Foundation"},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helsinki University Hospital Research and Education Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune protection against coronavirus disease 2019 (COVID-19) relies, along with cellular immunity, on anti\u2013severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We studied the effect of IgG avidity, the average antibody binding strength, on anti-SARS-CoV-2 neutralizing antibodies (nAbs), often considered the hallmark of effective immunity. Prior studies estimating the significance of avidity for nAb-mediated immunity have been complicated by the fact that not only the quality but also the quantity of antibodies impacts the results. Here we provide means for quantifying the impact of IgG avidity on neutralization, irrespective of antibody titer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We introduce for anti-SARS-CoV-2 spike protein (S) and nucleoprotein (N) antibodies, IgG avidity assays shown to be unaffected by the IgG concentration. Hospitalized (n = 14) and nonhospitalized (n = 14) COVID-19 patients and vaccinees (n = 20) of early 2020 were assayed for Wuhan S-IgM, S-IgA, S-IgG, and S-IgG avidity; Wuhan N-IgG and N-IgG avidity; and Wuhan, Beta, and Delta nAbs, to identify the factors contributing to neutralization efficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>N-IgG avidity was superior to S-avidity in pinpointing the time of SARS-CoV-2 primary infection. Both Wuhan nAb and Delta nAb correlated, expectedly, with Wuhan S-IgG level (P &amp;lt; .0001 each). Wuhan S-IgG avidity intensified homologous (Wuhan; P = .001) but not significantly heterologous (Delta; P = .053) neutralization. Accordingly, along with postinfection time, the average neutralization efficiency of S-IgG molecules increased while their concentration decreased. Quantitatively, doubling of Wuhan S-IgG avidity, at constant S-IgG quantity, augmented Wuhan neutralization 1.58- to 1.68-fold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Comprehensive serological profiles of early SARS-CoV-2 primary infections and immunizations provided a model showing that the antiviral neutralization potency is enhanced by anti-spike IgG avidity. The methodology presented is applicable widely beyond COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag068","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T12:33:45Z","timestamp":1770554025000},"page":"e1374-e1385","source":"Crossref","is-referenced-by-count":1,"title":["Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8052-5592","authenticated-orcid":false,"given":"Visa","family":"Nurmi","sequence":"first","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Hedman","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katariina","family":"Vapalahti","sequence":"additional","affiliation":[{"name":"Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Department of Medical and Clinical Genetics, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-214X","authenticated-orcid":false,"given":"Jussi","family":"Hepojoki","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Institute of Veterinary Pathology, Vetsuisse Faculty, University of Z\u00fcrich , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-7847","authenticated-orcid":false,"given":"Hasan","family":"U\u011furlu","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Department of Molecular Biology and Genetics, Faculty of Sciences, Erzurum Technical University , Erzurum ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-5515","authenticated-orcid":false,"given":"Rommel","family":"Iheozor-Ejiofor","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanice","family":"Knight","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-122X","authenticated-orcid":false,"given":"Kalle","family":"Saksela","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Helsinki University Hospital and University of Helsinki HUS Diagnostic Center, Clinical Microbiology, , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Kantele","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inflammation Centre, University of Helsinki and Helsinki University Hospital , Helsinki ,","place":["Finland"]},{"name":"Human Microbiome Research Unit, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Meilahti Vaccine Research Center MeVac, University of Helsinki and Helsinki University Hospital , Helsinki ,","place":["Finland"]},{"name":"Finnish Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, University of Helsinki FIMAR, , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1779-7960","authenticated-orcid":false,"given":"Klaus","family":"Hedman","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Helsinki University Hospital and University of Helsinki HUS Diagnostic Center, Clinical Microbiology, , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-6824","authenticated-orcid":false,"given":"Olli","family":"Vapalahti","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Helsinki University Hospital and University of Helsinki HUS Diagnostic Center, Clinical Microbiology, , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026061615203993400_jiag068-B1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2026061615203993400_jiag068-B2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"2026061615203993400_jiag068-B3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/v15040967","article-title":"SARS-CoV-2 reinfection and severity of the disease: a systematic review and meta-analysis","volume":"15","author":"Nguyen","year":"2023","journal-title":"Viruses"},{"key":"2026061615203993400_jiag068-B4","doi-asserted-by":"crossref","first-page":"924\u201344","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"2026061615203993400_jiag068-B5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiac492","article-title":"Antibody avidity maturation following recovery from infection or the booster vaccination grants breadth of SARS-CoV-2 neutralizing capacity","volume":"227","author":"Nakagama","year":"2023","journal-title":"J Infect Dis"},{"key":"2026061615203993400_jiag068-B6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3390\/v14071491","article-title":"Kinetics of the SARS-CoV-2 antibody avidity response following infection and vaccination","volume":"14","author":"Garcia","year":"2022","journal-title":"Viruses"},{"key":"2026061615203993400_jiag068-B7","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1038\/s41467-022-32298-w","article-title":"Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination","volume":"13","author":"Bellusci","year":"2022","journal-title":"Nat Commun"},{"key":"2026061615203993400_jiag068-B8","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/infdis\/jiaa581","article-title":"SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors","volume":"222","author":"Benner","year":"2020","journal-title":"J Infect Dis"},{"key":"2026061615203993400_jiag068-B9","doi-asserted-by":"crossref","first-page":"4813199","DOI":"10.1155\/2022\/4813199","article-title":"Antibody avidity and neutralizing response against SARS-CoV-2 Omicron variant after infection or vaccination","volume":"2022","author":"Dapporto","year":"2022","journal-title":"J Immunol Res"},{"key":"2026061615203993400_jiag068-B10","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J Clin Invest"},{"key":"2026061615203993400_jiag068-B11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.immuni.2021.06.015","article-title":"Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants","volume":"54","author":"Saya","year":"2021","journal-title":"Immunity"},{"key":"2026061615203993400_jiag068-B12","doi-asserted-by":"crossref","first-page":"2215677","DOI":"10.1080\/21645515.2023.2215677","article-title":"SARS-CoV-2 IgG spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines","volume":"19","author":"Hickey","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026061615203993400_jiag068-B13","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1002\/jmv.27270","article-title":"Vaccination versus infection with SARS-CoV-2: establishment of a high avidity IgG response versus incomplete avidity maturation","volume":"93","author":"Struck","year":"2021","journal-title":"J Med Virol"},{"key":"2026061615203993400_jiag068-B14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat Med"},{"key":"2026061615203993400_jiag068-B15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/infdis\/jiab300","article-title":"Marked increase in avidity of SARS-CoV-2 antibodies 7\u20138 months after infection is not diminished in old age","volume":"224","author":"Pichler","year":"2021","journal-title":"J Infect Dis"},{"key":"2026061615203993400_jiag068-B16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/infdis\/jiac379","article-title":"Regimen of coronavirus disease 2019 vaccination influences extent and kinetics of antibody avidity","volume":"226","author":"R\u00f6ssler","year":"2022","journal-title":"J Infect Dis"},{"key":"2026061615203993400_jiag068-B17","doi-asserted-by":"crossref","first-page":"104294","DOI":"10.1016\/j.ebiom.2022.104294","article-title":"Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"85","author":"Vogel","year":"2022","journal-title":"EBioMedicine"},{"key":"2026061615203993400_jiag068-B18","doi-asserted-by":"crossref","first-page":"eabf2467","DOI":"10.1126\/sciadv.abf2467","article-title":"Longitudinal antibody repertoire in \u201cmild\u201d versus \u201csevere\u201d COVID-19 patients reveals immune markers associated with disease severity and resolution","volume":"7","author":"Ravichandran","year":"2021","journal-title":"Sci Adv"},{"key":"2026061615203993400_jiag068-B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.37349\/ei.2022.00040","article-title":"High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity","volume":"2","author":"Bauer","year":"2022","journal-title":"Explor Immunol"},{"key":"2026061615203993400_jiag068-B20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061615203993400_jiag068-B21","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for Covid-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061615203993400_jiag068-B22","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Writing Committee for the REMAP-CAP Investigators","year":"2021","journal-title":"JAMA"},{"key":"2026061615203993400_jiag068-B23","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"B\u00e9gin","year":"2021","journal-title":"Nat Med"},{"key":"2026061615203993400_jiag068-B24","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1186\/s12879-021-06829-7","article-title":"Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials","volume":"21","author":"Axfors","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026061615203993400_jiag068-B25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/23744235.2024.2329957","article-title":"Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients\u2019 variants","volume":"56","author":"Khawaja","year":"2024","journal-title":"Infect Dis (Lond)"},{"key":"2026061615203993400_jiag068-B26","doi-asserted-by":"crossref","first-page":"106412","DOI":"10.1016\/j.jinf.2025.106412","article-title":"Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial","volume":"90","author":"Nurmi","year":"2025","journal-title":"J Infect"},{"key":"2026061615203993400_jiag068-B27","first-page":"572","article-title":"On the doctrine of original antigenic sin","volume":"104","author":"Francis","year":"1960","journal-title":"Proc Am Philos Soc"},{"key":"2026061615203993400_jiag068-B28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/v13020143","article-title":"A 10-minute \u201cmix and read\u201d antibody assay for SARS-CoV-2","volume":"13","author":"Rusanen","year":"2021","journal-title":"Viruses"},{"key":"2026061615203993400_jiag068-B29","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1002\/cpmc.100","article-title":"SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup","volume":"57","author":"Stadlbauer","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"2026061615203993400_jiag068-B30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijid.2021.05.047","article-title":"Comparison of approaches for IgG avidity calculation and a new highly sensitive and specific method with broad dynamic range","volume":"110","author":"Nurmi","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026061615203993400_jiag068-B31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jiad070","article-title":"The relationship between SARS-CoV-2 neutralizing antibody titers and avidity in plasma collected from convalescent nonvaccinated and vaccinated blood donors","volume":"228","author":"Nurmi","year":"2023","journal-title":"J Infect Dis"},{"key":"2026061615203993400_jiag068-B32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00917569","article-title":"Recent rubella virus infection indicated by a low avidity of specific IgG","volume":"8","author":"Hedman","year":"1988","journal-title":"J Clin Immunol"},{"key":"2026061615203993400_jiag068-B33","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/jcm.35.8.1972-1977.1997","article-title":"Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity","volume":"35","author":"Jenum","year":"1997","journal-title":"J Clin Microbiol"},{"key":"2026061615203993400_jiag068-B34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2334-4-33","article-title":"A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid","volume":"4","author":"Kneitz","year":"2004","journal-title":"BMC Infect Dis"},{"key":"2026061615203993400_jiag068-B35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/JCM.01076-08","article-title":"Development of fully automated determination of marker-specific immunoglobulin G (IgG) avidity based on the avidity competition assay format: application for Abbott Architect cytomegalovirus and Toxo IgG avidity assays","volume":"47","author":"Curdt","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2026061615203993400_jiag068-B36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41467-023-37290-6","article-title":"Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants","volume":"14","author":"M\u00e4kel\u00e4","year":"2023","journal-title":"Nat Commun"},{"key":"2026061615203993400_jiag068-B37","author":"Harrell"},{"key":"2026061615203993400_jiag068-B38","author":"Taiyun"},{"key":"2026061615203993400_jiag068-B39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2021.01.061","article-title":"The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2","volume":"106","author":"Bauer","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026061615203993400_jiag068-B40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/v14030532","article-title":"Evolution of anti-RBD IgG avidity following SARS-CoV-2 infection","volume":"14","author":"Tauzin","year":"2022","journal-title":"Viruses"},{"key":"2026061615203993400_jiag068-B41","doi-asserted-by":"crossref","first-page":"105052","DOI":"10.1016\/j.jcv.2021.105052","article-title":"Antibody response to SARS-CoV-2 for more than one year\u2014kinetics and persistence of detection are predominantly determined by avidity progression and test design","volume":"146","author":"Scheiblauer","year":"2022","journal-title":"J Clin Virol"},{"key":"2026061615203993400_jiag068-B42","doi-asserted-by":"crossref","first-page":"100892","DOI":"10.1016\/j.lanepe.2024.100892","article-title":"Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European Congenital Infection Initiative (ECCI)","volume":"40","author":"Leruez-Ville","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026061615203993400_jiag068-B43","doi-asserted-by":"crossref","first-page":"1184362","DOI":"10.3389\/fimmu.2023.1184362","article-title":"Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature","volume":"14","author":"Cantoni","year":"2023","journal-title":"Front Immunol"},{"key":"2026061615203993400_jiag068-B44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","article-title":"Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting","volume":"625","author":"Yisimayi","year":"2024","journal-title":"Nature"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag068\/67227534\/jiag068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/e1374\/67227534\/jiag068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/e1374\/67227534\/jiag068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:20:52Z","timestamp":1781637652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/6\/e1374\/8505856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag068","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,3,5]]}}}